Global COVID-19 Prevention Trial of Hydroxychloroquine to Resume
07/01/2020
A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators, according to a Reuters report.
The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with COVID-19, the disease caused by the new coronavirus. The COPCOV study was paused pending review after the treatment trial results.